The JV will establish a state-of-the-art manufacturing facility to manufacture fermented animal free protein to cater to the global markets
Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
Revolutionary technology will further boost OneSource’s scientific services offerings
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
Shilpa Biologicals has developed high concentration adalimumab (100 mg/mL)
Reported profit after tax declined 19% year-on-year to Rs 76 crores
Protein research is key to advancing our understanding of human biology and delivering on the promise of precision medicine
Globally, colorectal cancer impacts 1.9 million people each year, standing as a leading cause of cancer mortality
Utidelone can penetrate BBB due to its unique physicochemical characteristics and insusceptibility to P-glycoprotein-mediated efflux
Subscribe To Our Newsletter & Stay Updated
